{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:13:42Z","timestamp":1771467222812,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The Dafodil\u2122-1 trial was designed to evaluate the clinical safety and performance of Dafodil\u2122 pericardial bioprosthesis for replacing diseased native or prosthetic aortic or mitral valves in patients with advanced valvular heart disease (VHD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Dafodil\u2122-1 trial was a prospective, multicenter, first-in-human clinical trial. Patients were enrolled if they had advanced VHD requiring aortic valve replacement (AVR) or mitral valve replacement (MVR) with or without concomitant valve surgery and having surgical risk scores &amp;lt;4%. Major adverse cardiac events (MACE), including all-cause death, myocardial infarction (MI), and stroke; and hemodynamics were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 136 patients (aortic: 67 and mitral: 69) were enrolled in the trial (with mean age\u2014AVR group: 60.2\u2009\u00b1\u20098.3 years and MVR group: 49.7\u2009\u00b1\u200914.4 years). A total of 134 patients (aortic: 66 and mitral: 68) completed the 3-year follow-up (total 300 per 100 patient-years of follow-up). The AVR group demonstrated a significant reduction in the mean pressure gradients from 51.2\u2009\u00b1\u200924.1\u2005mmHg at baseline to 11.1\u2009\u00b1\u20096.0\u2005mmHg at the 3-year follow-up (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001). The mean effective orifice area (EOA) improved from baseline (0.9\u2009\u00b1\u20090.6\u2005cm<jats:sup>2<\/jats:sup>) to 3-year follow-up (1.8\u2009\u00b1\u20090.4\u2005cm<jats:sup>2<\/jats:sup>) (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001). In the MVR group, the mean indexed EOA (iEOA) increased significantly from baseline (0.7\u2009\u00b1\u20090.4\u2005cm<jats:sup>2<\/jats:sup>\/m<jats:sup>2<\/jats:sup>) to 3-year follow-up (1.1\u2009\u00b1\u20090.4\u2005cm<jats:sup>2<\/jats:sup>\/m<jats:sup>2<\/jats:sup>) (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). There was significant improvement in New York Heart Association functional class and mean SF-12 scores in both groups. At 3-year follow-up, the MACE incidence was 2.3% per 100 patient-years (1.3% strokes per 100 patient-years and 1.3% deaths per 100 patient-years) for AVR group and 4.7% per 100 patient-years (0.6% strokes per 100 patient-years and 4.0% deaths per 100 patient-years) for MVR group. No cases of MI, structural valve deterioration and prosthetic valve endocarditis were reported. The AVR and MVR groups achieved 89.6% and 79.7% MACE-free survival, respectively at 3-year follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The Dafodil\u2122-1 trial demonstrated satisfactory outcomes of clinical safety, hemodynamic performance, and quality-of-life metrics. Additionally, no incidence of structural valve deterioration and very low rates of valve thrombosis during the 3-year follow-up period of Dafodil\u2122-1 first-in-human trial indicated acceptable valve durability up to three years and similar outcomes are warranted for longer follow-ups as a primary goal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration Number<\/jats:title><jats:p><jats:ext-link>https:\/\/www.ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=18377&amp;amp;EncHid=&amp;amp;userName=CTRI\/2017\/07\/009008<\/jats:ext-link>, CTRI\/2017\/07\/009008.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1393762","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:52:22Z","timestamp":1717077142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Three-year outcomes of surgical valve replacement with Dafodil\u2122 pericardial bioprosthesis: Dafodil\u2122-1 trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Channabasavaraj Shivalingaiah","family":"Hiremath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil R.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul A.","family":"Maslekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binay Krishna","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seetharama","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Porwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zile Singh","family":"Meharwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugal Kishore","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Vaijyanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subash S.","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Sethuratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naman","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"658016","DOI":"10.3389\/fcvm.2021.658016","article-title":"Patient-tailored aortic valve replacement","volume":"8","author":"De Backer","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/jama.2014.12679","article-title":"Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years","volume":"312","author":"Chiang","year":"2014","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ejcts\/ezx117","article-title":"Ten-year results of aortic valve replacement with first-generation mitroflow bioprosthesis: is early degeneration a structural or a technical issue?","volume":"52","author":"Lootens","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0040-1721189","article-title":"Technical details of aortic valve replacement using carpentier\u2013edwards PERIMOUNT magna ease aortic bioprosthesis in a sexagenarian patient with severe calcific aortic stenosis: a video presentation","volume":"4","author":"Chowdhury","year":"2020","journal-title":"J Cardiac Crit Care TSS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2013\/728791","article-title":"Bioprosthetic heart valves: impact of implantation on biomaterials","volume":"2013","author":"Singhal","year":"2013","journal-title":"ISRN Biomater"},{"key":"B7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.athoracsur.2019.07.024","article-title":"Durability of mitral valve bioprostheses: a meta-analysis of long-term follow-up studies","volume":"109","author":"Malvindi","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"B8","article-title":"Valvular Heart Disease (Figure 3)","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ihj.2020.06.013","article-title":"Etiology and distribution of isolated aortic stenosis in Indian patients\u2014a study from a large tertiary care hospital in North India","volume":"72","author":"Sahu","year":"2020","journal-title":"Indian Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12055-008-0003-7","article-title":"Tissue heart valve implantation in India; indications, results, and impact on quality of life","volume":"24","author":"Talwar","year":"2008","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s1054-8807(03)00075-9","article-title":"The evolution of bioprosthetic heart valve design and its impact on durability","volume":"12","author":"Vesely","year":"2003","journal-title":"Cardiovasc Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13019-020-01154-7","article-title":"Clinical outcomes and hemodynamic performance of dafodil\u2122 aortic and mitral pericardial bioprosthesis: 1-year results from Dafodil-1 first-in-human trial","volume":"15","author":"Hiremath","year":"2020","journal-title":"J Cardiothorac Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.echo.2009.07.013","article-title":"; American society of echocardiography\u2019s guidelines and standards committee; task force on prosthetic valves","volume":"22","author":"Zoghbi","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.athoracsur.2021.12.058","article-title":"Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue","volume":"115","author":"Bavaria","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2021.12.058","article-title":"The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue","volume":"52","author":"Bavaria","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jtcvs.2020.01.095","article-title":"Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue","volume":"162","author":"Johnston","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.xjon.2023.05.008","article-title":"Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue","volume":"15","author":"Heimansohn","year":"2023","journal-title":"JTCVS Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jtcvs.2019.10.095","article-title":"Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis","volume":"161","author":"Klautz","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ezac374","DOI":"10.1093\/ejcts\/ezac374","article-title":"Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes","volume":"62","author":"Klautz","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1067\/mtc.2002.122552","article-title":"European experience with the mosaic bioprosthesis","volume":"124","author":"Eichinger","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/CIRCULATIONAHA.118.038408","article-title":"Aortic stenosis and small aortic annulus","volume":"139","author":"Freitas-Ferraz","year":"2019","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1111\/jocs.17140","article-title":"Eight-year outcomes of aortic valve replacement with the carpentier-edwards PERIMOUNT magna ease valve","volume":"37","author":"Tsui","year":"2022","journal-title":"J Card Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jtcvs.2010.08.090","article-title":"Medtronic mosaic porcine bioprosthesis: assessment of 12-year performance","volume":"142","author":"Jamieson","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1253\/circj.CJ-19-1113","article-title":"Long-term outcomes of the mosaic aortic porcine bioprosthesis in Japan\u2014results from the Japan mosaic valve long-term multicenter study","volume":"84","author":"Yoshikawa","year":"2020","journal-title":"Circ J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14503\/THIJ-14-4407","article-title":"The mosaic mitral valve bioprosthesis: a long-term clinical and hemodynamic follow-up","volume":"43","author":"Celiento","year":"2016","journal-title":"Tex Heart Inst J"},{"key":"B28","first-page":"641","article-title":"Mid-term results after epic xenograft implantation for aortic, mitral, and double valve replacement","volume":"16","author":"Lehmann","year":"2007","journal-title":"J Heart Valve Dis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1393762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:33:38Z","timestamp":1721385218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1393762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2024.1393762"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1393762","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1393762"}}